Skip to main content
SpringerLink
Log in

Proton pump inhibitors and clopidogrel: an association to avoid?

  • IM - REVIEW
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Dual antiplatelet therapy with aspirin and clopidogrel reduces cardiovascular events following an acute coronary syndrome or stent implantation, but the associated increased risk of gastro-intestinal bleeding often leads to the co-administration of proton pump inhibitors (PPIs). PPIs have been shown to decrease antiplatelet effects of clopidogrel ex vivo, raising concerns about the cardiovascular safety of this drug combination. Clinical trials investigating PPI–clopidogrel interactions have provided conflicting results and are all subject to methodological critiques. The much desired and much needed prospective, double-bind, randomized, placebo-controlled trials with adequate follow-up and sample size have not yet been performed. Indeed, the Clopidogrel and the Optimization of GI Events Trial, which would have had such characteristics, was stopped prematurely. As a consequence, the question of the PPI–clopidogrel interaction is still unresolved, and clinical consequences cannot be excluded. At this time such combination therapy should, therefore, be provisionally advocated only for patients at high risk of bleeding (prior upper gastro-intestinal bleeding, advanced age, concomitant use of warfarin, steroidal or non-steroidal anti-inflammatory drugs and Helicobacter pylori infection) and avoiding PPIs with strong affinity for cytochrome CYP2C19, such as omeprazole and esomeprazole.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497):1607–1621. doi:10.1016/S0140-6736(05)67660-X

    Article  CAS  PubMed  Google Scholar 

  2. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352(12):1179–1189. doi:10.1056/NEJMoa050522

    Article  CAS  PubMed  Google Scholar 

  3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494–502. doi:10.1056/NEJMoa010746

    Article  CAS  PubMed  Google Scholar 

  4. Centemero MP, Stadler JR (2012) Stent thrombosis: an overview. Expert Rev Cardiovasc Ther 10(5):599–615. doi:10.1586/erc.12.38

    Article  PubMed  Google Scholar 

  5. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S, Achenbach S, Badimon L, Bertrand M, Botker HE, Collet JP, Crea F, Danchin N, Falk E, Goudevenos J, Gulba D, Hambrecht R, Herrmann J, Kastrati A, Kjeldsen K, Kristensen SD, Lancellotti P, Mehilli J, Merkely B, Montalescot G, Neumann FJ, Neyses L, Perk J, Roffi M, Romeo F, Ruda M, Swahn E, Valgimigli M, Vrints CJ, Widimsky P (2011) ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. doi:10.1093/eurheartj/ehr236

    Google Scholar 

  6. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP (2012) ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 60(7):645–681. doi:10.1016/j.jacc.2012.06.004

    Article  PubMed  Google Scholar 

  7. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011) ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 124(23):2574–2609. doi:10.1161/CIR.0b013e31823a5596

    Article  PubMed  Google Scholar 

  8. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX (2012) ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. doi:10.1161/CIR.0b013e3182742c84

    Google Scholar 

  9. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D (2010) Guidelines on myocardial revascularization. Eur Heart J 31(20):2501–2555. doi:10.1093/eurheartj/ehq277

    Article  PubMed  Google Scholar 

  10. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, Fitzgerald D, Hirsh J, Husted S, Kvasnicka J, Montalescot G, Garcia Rodriguez LA, Verheugt F, Vermylen J, Wallentin L, Priori SG, Alonso Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Fernandez Burgos E, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Ferreira R, Steg PG, Teixeira F, Wilcox R (2004) Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 25(2):166–181 (pii:S0195668X03006894)

    Article  PubMed  Google Scholar 

  11. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF (2010) ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 56(24):2051–2066. doi:10.1016/j.jacc.2010.09.010

    Article  PubMed  Google Scholar 

  12. Harrison RW, Mahaffey KW (2011) Clopidogrel and PPI interaction: clinically relevant or not? Curr Cardiol Rep. doi:10.1007/s11886-011-0233-y

    Google Scholar 

  13. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, Brennan DM, Hacke W, Montalescot G, Steinhubl SR, Topol EJ (2010) Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 121(23):2575–2583. doi:10.1161/CIRCULATIONAHA.109.895342

    Article  CAS  PubMed  Google Scholar 

  14. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51(3):256–260. doi:10.1016/j.jacc.2007.06.064

    Article  CAS  PubMed  Google Scholar 

  15. Norgard NB, Mathews KD, Wall GC (2009) Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother 43(7):1266–1274. doi:10.1345/aph.1M051

    Article  CAS  PubMed  Google Scholar 

  16. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38(1):92–99. doi:10.1124/dmd.109.029132

    Article  CAS  PubMed  Google Scholar 

  17. Blume H, Donath F, Warnke A, Schug BS (2006) Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 29(9):769–784 (pii:2992)

    Article  CAS  PubMed  Google Scholar 

  18. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schomig A, Kastrati A, von Beckerath N (2009) Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101(4):714–719 (pii:09040714)

    CAS  PubMed  Google Scholar 

  19. Jungnickel PW (2000) Pantoprazole: a new proton pump inhibitor. Clin Ther 22(11):1268–1293 (pii:S0149-2918(00)83025-8)

    Article  CAS  PubMed  Google Scholar 

  20. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660):309–317. doi:10.1016/S0140-6736(08)61845-0

    Article  CAS  PubMed  Google Scholar 

  21. Khalique SC, Cheng-Lai A (2009) Drug interaction between clopidogrel and proton pump inhibitors. Cardiol Rev 17(4):198–200. doi:10.1097/CRD.0b013e3181a857ba

    Article  PubMed  Google Scholar 

  22. Jakubowski J, Winters K, Naganuma H, Wallentin L (2007) Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 25:357–374

    Article  CAS  PubMed  Google Scholar 

  23. Wallentin L (2009) P2Y12 inhibitors: differences in properties and mechanism of action and potential consequences for clinical use. Eur Heart J 30:1964–1977

    Article  CAS  PubMed  Google Scholar 

  24. Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, Mahaffey KW, Angiolillo DJ, Husted S, Cannon CP, James SK, Kilhamn J, Steg PG, Harrington RA, Wallentin L (2012) Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation 125(8):978–986. doi:10.1161/CIRCULATIONAHA.111.032912

    Article  CAS  PubMed  Google Scholar 

  25. Wiviott SD, Antman EM (2004) Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 109(25):3064–3067. doi:10.1161/01.CIR.0000134701.40946.30

    Article  PubMed  Google Scholar 

  26. Nguyen TA, Diodati JG, Pharand C (2005) Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45(8):1157–1164. doi:10.1016/j.jacc.2005.01.034

    Article  CAS  PubMed  Google Scholar 

  27. Gorchakova O, von Beckerath N, Gawaz M, Mocz A, Joost A, Schomig A, Kastrati A (2004) Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 25(21):1898–1902. doi:10.1016/j.ehj.2003.10.039

    Article  CAS  PubMed  Google Scholar 

  28. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. Circulation 107(1):32–37

    Article  CAS  PubMed  Google Scholar 

  29. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD (2004) Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 109(11):1335–1338. doi:10.1161/01.CIR.0000124581.18191.15

    Article  CAS  PubMed  Google Scholar 

  30. Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A (2003) Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function—a flow cytometry study. Eur Heart J 24(19):1744–1749 (pii:S0195668X03004421)

    Article  CAS  PubMed  Google Scholar 

  31. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ (2003) Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108(8):921–924. doi:10.1161/01.CIR.0000088780.57432.43

    Article  CAS  PubMed  Google Scholar 

  32. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, Tanguay JF, Steinhubl SR, Berger PB, O’Connor CM, Hennekens CH (2004) Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 164(18):2051–2057. doi:10.1001/archinte.164.18.2051

    Article  CAS  PubMed  Google Scholar 

  33. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108(7):2244–2247. doi:10.1182/blood-2006-04-013052

    Article  CAS  PubMed  Google Scholar 

  34. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR (2011) Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 90(2):328–332. doi:10.1038/clpt.2011.132

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41(12):913–958 (pii:411202)

    Article  CAS  PubMed  Google Scholar 

  36. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T (2005) Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20(3):153–167 (pii:JST.JSTAGE/dmpk/20.153)

    Article  CAS  PubMed  Google Scholar 

  37. Yang JC, Lin CJ (2010) CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opin Drug Metab Toxicol 6(1):29–41. doi:10.1517/17425250903386251

    Article  CAS  PubMed  Google Scholar 

  38. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5(12):2429–2436. doi:10.1111/j.1538-7836.2007.02775.x

    Article  CAS  PubMed  Google Scholar 

  39. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52(4):349–355 (pii:1499)

    Article  CAS  PubMed  Google Scholar 

  40. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER (2004) Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109(2):166–171. doi:10.1161/01.CIR.0000112378.09325.F9

    Article  CAS  PubMed  Google Scholar 

  41. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360(4):354–362. doi:10.1056/NEJMoa0809171

    Article  CAS  PubMed  Google Scholar 

  42. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Buttner HJ, Neumann FJ (2008) Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51(20):1925–1934. doi:10.1016/j.jacc.2007.12.056

    Article  CAS  PubMed  Google Scholar 

  43. Umemura K, Furuta T, Kondo K (2008) The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 6(8):1439–1441. doi:10.1111/j.1538-7836.2008.03050.x

    Article  CAS  PubMed  Google Scholar 

  44. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dorrler K, Morath T, Schomig A, Kastrati A, von Beckerath N (2009) Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30(8):916–922. doi:10.1093/eurheartj/ehp041

    Article  CAS  PubMed  Google Scholar 

  45. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J (2006) Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 4(11):2508–2509. doi:10.1111/j.1538-7836.2006.02162.x

    Article  CAS  PubMed  Google Scholar 

  46. Parri MS, Gianetti J, Dushpanova A, Della Pina F, Saracini C, Marcucci R, Giusti B, Berti S (2012) Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: results of a pilot randomized trial. Int J Cardiol. doi:10.1016/j.ijcard.2012.05.080

    PubMed  Google Scholar 

  47. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE, Winters KJ (2008) Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 48(4):475–484. doi:10.1177/0091270008315310

    Article  CAS  PubMed  Google Scholar 

  48. Zuern CS, Geisler T, Lutilsky N, Winter S, Schwab M, Gawaz M (2010) Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. Thromb Res 125(2):e51–e54. doi:10.1016/j.thromres.2009.08.016

    Article  PubMed  Google Scholar 

  49. Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, Brissy O, Morange PE, Alessi MC, Bonnet JL (2009) Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 54(13):1149–1153. doi:10.1016/j.jacc.2009.05.050

    Article  CAS  PubMed  Google Scholar 

  50. Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, LaCreta FP, Hurbin F, Dubar M (2011) Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 89(1):65–74. doi:10.1038/clpt.2010.219

    Article  CAS  PubMed  Google Scholar 

  51. Fontes-Carvalho R, Albuquerque A, Araujo C, Pimentel-Nunes P, Ribeiro VG (2011) Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel–PPIs drug interaction. Eur J Gastroenterol Hepatol 23(5):396–404. doi:10.1097/MEG.0b013e3283460110

    Article  CAS  PubMed  Google Scholar 

  52. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301(9):937–944. doi:10.1001/jama.2009.261

    Article  CAS  PubMed  Google Scholar 

  53. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180(7):713–718. doi:10.1503/cmaj.082001

    Article  PubMed Central  PubMed  Google Scholar 

  54. Kreutz RP, Stanek EJ, Aubert R, Yao J, Breall JA, Desta Z, Skaar TC, Teagarden JR, Frueh FW, Epstein RS, Flockhart DA (2010) Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy 30(8):787–796. doi:10.1592/phco.30.8.787

    Article  CAS  PubMed  Google Scholar 

  55. Gaglia MA Jr, Torguson R, Hanna N, Gonzalez MA, Collins SD, Syed AI, Ben-Dor I, Maluenda G, Delhaye C, Wakabayashi K, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R (2010) Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes. Am J Cardiol 105(6):833–838. doi:10.1016/j.amjcard.2009.10.063

    Article  CAS  PubMed  Google Scholar 

  56. Burkard T, Kaiser CA, Brunner-La Rocca H, Osswald S, Pfisterer ME, Jeger RV (2012) Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. J Intern Med 271(3):257–263. doi:10.1111/j.1365-2796.2011.02423.x

    Article  CAS  PubMed  Google Scholar 

  57. Bhurke SM, Martin BC, Li C, Franks AM, Bursac Z, Said Q (2012) Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy 32(9):809–818. doi:10.1002/j.1875-9114.2012.01112.x

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. Huang B, Huang Y, Li Y, Yao H, Jing X, Huang H, Li J (2012) Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Arch Med Res 43(3):212–224. doi:10.1016/j.arcmed.2012.04.004

    Article  CAS  PubMed  Google Scholar 

  59. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW (2010) The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. J Cardiovasc Pharmacol 56(5):532–539. doi:10.1097/FJC.0b013e3181f68209

    Article  CAS  PubMed  Google Scholar 

  60. Dunn SP (2008) Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 118(A:3999):815

    Google Scholar 

  61. Aubert RE (2008) Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study. Circulation 118(A:3998):S815

    Google Scholar 

  62. O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD (2009) Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374(9694):989–997. doi:10.1016/S0140-6736(09)61525-7

    Article  PubMed  Google Scholar 

  63. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S (2009) Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 120(23):2322–2329. doi:10.1161/CIRCULATIONAHA.109.873497

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  64. Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, Daugherty JR, Kaltenbach LA, Stein CM (2010) Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 152(6):337–345. doi:10.1059/0003-4819-152-6-201003160-00003

    Article  PubMed Central  PubMed  Google Scholar 

  65. Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefevre T, Drouet E, Mulak G, Bataille V, Ferrieres J, Verstuyft C, Danchin N (2011) Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 123(5):474–482. doi:10.1161/CIRCULATIONAHA.110.965640

    Article  CAS  PubMed  Google Scholar 

  66. Tentzeris I, Jarai R, Farhan S, Brozovic I, Smetana P, Geppert A, Wojta J, Siller-Matula J, Huber K (2010) Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost 104(6):1211–1218. doi:10.1160/TH10-04-0218

    Article  CAS  PubMed  Google Scholar 

  67. Aihara H, Sato A, Takeyasu N, Nishina H, Hoshi T, Akiyama D, Kakefuda Y, Watabe H, Aonuma K (2012) Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry. Catheter Cardiovasc Interv. doi:10.1002/ccd.23327

    PubMed  Google Scholar 

  68. Chitose T, Hokimoto S, Oshima S, Nakao K, Fujimoto K, Miyao Y, Shimomura H, Tsunoda R, Maruyama H, Hirose T, Yamamoto K, Mizobe M, Kaikita K, Nakamura S, Ogawa H (2012) Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor. Circ J 76(1):71–78 (pii:JST.JSTAGE/circj/CJ-11-0699)

    Article  CAS  PubMed  Google Scholar 

  69. Kwok CS, Loke YK (2010) Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 31(8):810–823. doi:10.1111/j.1365-2036.2010.04247.x

    CAS  PubMed  Google Scholar 

  70. Gerson LB, McMahon D, Olkin I, Stave C, Rockson SG (2011) Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature. Dig Dis Sci. doi:10.1007/s10620-011-2007-1

    PubMed  Google Scholar 

  71. Kwok CS, Jeevanantham V, Dawn B, Loke YK (2012) No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. doi:10.1016/j.ijcard.2012.03.085

    PubMed  Google Scholar 

  72. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP (2010) Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363(20):1909–1917. doi:10.1056/NEJMoa1007964

    Article  CAS  PubMed  Google Scholar 

  73. Charlot M, Ahlehoff O, Norgaard ML, Jorgensen CH, Sorensen R, Abildstrom SZ, Hansen PR, Madsen JK, Kober L, Torp-Pedersen C, Gislason G (2010) Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 153(6):378–386. doi:10.1059/0003-4819-153-6-201009210-00005

    Article  PubMed  Google Scholar 

  74. Douglas IJ, Evans SJ, Hingorani AD, Grosso AM, Timmis A, Hemingway H, Smeeth L (2012) Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ 345:e4388

    Article  PubMed Central  PubMed  Google Scholar 

  75. Schmidt M, Johansen MB, Robertson DJ, Maeng M, Kaltoft A, Jensen LO, Tilsted HH, Botker HE, Sorensen HT, Baron JA (2012) Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther 35(1):165–174. doi:10.1111/j.1365-2036.2011.04890.x

    Article  CAS  PubMed  Google Scholar 

  76. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O, Cayla G, Beygui F, Montalescot G (2010) Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 56(2):134–143. doi:10.1016/j.jacc.2009.12.071

    Article  CAS  PubMed  Google Scholar 

  77. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Bujanda L, Gomollon F, Forne M, Aleman S, Nicolas D, Feu F, Gonzalez-Perez A, Borda A, Castro M, Poveda MJ, Arenas J (2007) Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 102(3):507–515. doi:10.1111/j.1572-0241.2006.01062.x

    Article  CAS  PubMed  Google Scholar 

  78. Ng FH, Wong SY, Lam KF, Chu WM, Chan P, Ling YH, Kng C, Yuen WC, Lau YK, Kwan A, Wong BC (2010) Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 138(1):82–88. doi:10.1053/j.gastro.2009.09.063

    Article  CAS  PubMed  Google Scholar 

  79. Rendic S (1999) Drug interactions of H2-receptor antagonists involving cytochrome P450 (CYPs) enzymes: from the laboratory to the clinic. Croat Med J 40(3):357–367

    CAS  PubMed  Google Scholar 

  80. Tran M, Tafreshi J, Pai RG (2010) Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians. J Cardiovasc Pharmacol Ther 15(4):326–337. doi:10.1177/1074248410369109

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Institute of Cardiology and Center of Excellence on Aging, “G. d’Annunzio” University-Chieti, C/o Ospedale SS. Annunziata, Via dei Vestini, 66013, Chieti, Italy

    Emilia D’Ugo, Serena Rossi & Raffaele De Caterina

  2. G. Monasterio Foundation, Pisa, Italy

    Raffaele De Caterina

Authors
  1. Emilia D’Ugo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serena Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raffaele De Caterina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raffaele De Caterina.

Rights and permissions

Reprints and permissions

About this article

Cite this article

D’Ugo, E., Rossi, S. & De Caterina, R. Proton pump inhibitors and clopidogrel: an association to avoid?. Intern Emerg Med 9, 11–22 (2014). https://doi.org/10.1007/s11739-013-1000-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-013-1000-4

Keywords

Search

Navigation